

QuantiGene® 2.0 Bibliography

2011

1. Babij C., *et al.* STK33 Kinase Activity is Non-Essential in KRAS-Dependent Cancer Cells. *Cancer Res* (2011).
2. Baughman J. M., *et al.* Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature* (2011).
3. Beare P. A., *et al.* Dot/Icm Type IVB Secretion System Requirements for *Coxiella burnetii* Growth in Human Macrophages. *MBio* **2**(4) (2011).
4. Bergemann T. L., Wilson, J. Proportion statistics to detect differentially expressed genes: a comparison with log-ratio statistics. *BMC Bioinformatics* **12**(1):228 (2011).
5. Brown M. L., *et al.* Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothed antagonist hit. *Bioorg Med Chem Lett* **21**(18):5206-9 (2011).
6. Cao G., *et al.* Evacetrapib is a novel, potent and selective inhibitor of cholesteryl ester transfer protein that elevates high-density lipoprotein cholesterol without inducing aldosterone or increasing blood pressure. *Journal of Lipid Research* (2011).
7. Cao Y. C., *et al.* Quantum dots high fluorescent signal amplification immunoassay using branched DNA and peptide nucleic acid conjugated antibody. *Analyst* (2011).
8. Chae B. J., *et al.* Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay. *Pathology* **43**(3):248-53 (2011).
9. Crombez L., *et al.* A Non-covalent Peptide-Based Strategy for Ex Vivo and In Vivo Oligonucleotide Delivery. *Methods Mol Biol* **764**:59-73 (2011).
10. Hinfray N. *et al.* Characterization of testicular expression of P450 17alpha-hydroxylase, 17,20-lyase in zebrafish and its perturbation by the pharmaceutical fungicide clotrimazole. *Gen Comp Endocrinol* (2011).
11. Hongyu Z., Wei Z., Chung L. Bias detection and correction in RNA-Sequencing data. *BMC Bioinformatics* **12**(1):290 (2011).
12. Kadota K., *et al.* Evaluating methods for ranking differentially expressed genes applied to MicroArray Quality Control data. *BMC Bioinformatics* **12**(1):227 (2011).
13. Lapierre J., *et al.* Potent and systematic RNAi mediated silencing with single oligonucleotide compounds. *Rna* **17**(6):1032-7 (2011).
14. Li M., *et al.* Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. *Microvasc Res* **81**(1):26-33 (2011).
15. Liao L. H., *et al.* Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic lupus erythematosus in Chinese population. *Arthritis Res Ther* **13**(1):R11 (2011).

QuantiGene® 2.0 Bibliography

16. Lin Y. Z., *et al.* The pathogenic and vaccine strains of equine infectious anemia virus differentially induce cytokine and chemokine expression and apoptosis in macrophages. *Virus Res* (2011).
17. Lu B., *et al.* The Role of the Transcription Factor SIM2 in Prostate Cancer. *PLoS ONE* **6**(12):e28837 (2011).
18. Lu H., *et al.* Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. *Toxicol Appl Pharmacol* (2011).
19. Martin S. E., *et al.* RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors. *Curr Cancer Drug Targets*(2011).
20. Mital J., *et al.* A role for the Src-family kinase Fyn in sphingolipid acquisition by chlamydiae. *Infect Immun* (2011).
21. Murray L. A., *et al.* TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. *Int J Biochem Cell Biol* **43**(1):154-62 (2011).
22. Polach K. J., *et al.* Delivery of siRNA to the Mouse Lung via a Functionalized Lipopolyamine. *Mol Ther* (2011).
23. Selvaduray K. R., *et al.* Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells. *Genes Nutr* (2011).
24. Torres J. Z., *et al.* The STARD9/Kif16a Kinesin Associates with Mitotic Microtubules and Regulates Spindle Pole Assembly. *Cell* **147**(6):1309-23 (2011).
25. Trabzuni D., *et al.* Quality control parameters on a large dataset of regionally-dissected human control brains for whole genome expression studies. *J Neurochem* (2011).
26. Voth D. E., *et al.* The *Coxiella burnetii* Cryptic Plasmid Is Enriched in Genes Encoding Type IV Secretion System Substrates. *J Bacteriol* **193**(7):1493-503 (2011).

2010

1. Abbott C., *et al.* Mouse monoclonal antibodies against human c-Mpl and characterization for flow cytometry applications. *Hybridoma (Larchmt)* **29**(2):103-13 (2010).
2. Addepalli H., *et al.* Modulation of thermal stability can enhance the potency of siRNA. *Nucleic Acids Res* (2010).
3. Akashi M., *et al.* Noninvasive method for assessing the human circadian clock using hair follicle cells. *Proc Natl Acad Sci U S A* **107**(35):15643-8 (2010).
4. Aleksunes L. M., *et al.* Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. *J Pharmacol Exp Ther* **333**(1):140-51 (2010).

QuantiGene® 2.0 Bibliography

5. Alnouti Y., Klaassen C. D. Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults). *Xenobiotica* (2010).
6. Berahovich R. D., et al. CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes. *J Immunol* (2010).
7. Chen Q., et al. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. *J Control Release* (2010).
8. Chen Z., Zhu L., Wilkinson K. J. Validation of the biotic ligand model in metal mixtures: bioaccumulation of lead and copper. *Environ Sci Technol* **44**(9): 3580-6 (2010).
9. Cheneval D., et al. A review of methods to monitor the modulation of mRNA stability: a novel approach to drug discovery and therapeutic intervention. *J Biomol Screen* **15**(6):609-22 (2010).
10. Cui J. Y., et al. Genetic and Epigenetic Regulation and Expression Signatures of Glutathione S-Transferases in Developing Mouse Liver. *Toxicol Sci* (2010).
11. Cui J. Y., et al. ChIPing the cistrome of PXR in mouse liver. *Nucleic Acids Res* (2010).
12. Debruin C., et al. Most purported antibodies to the human granulocyte colony-stimulating factor receptor are not specific. *Exp Hematol* (2010).
13. Ehsani A., et al. Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. *Mol Ther* **18**(4):796-802 (2010).
14. Erickson H .S., et al. High throughput screening of normal and neoplastic tissue samples. *Comb Chem High Throughput Screen* **13**(3):253-67 (2010).
15. Furusato B., et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. *Prostate Cancer Prostatic Dis* **13**(3):228-37 (2010).
16. Genter M. B., et al. Drug transporter expression and localization in rat nasal respiratory and olfactory mucosa and olfactory bulb. *Drug Metab Dispos* **38**(10):1644-7 (2010).
17. Haobin W., et al. Detection and clinical significance of CEA,GCC and CD44v6 mRNA in peritoneal lavages of colorectal cancer patients:report of 60 cases. *Acta Academiae Medicinae Militaris Tertiae* **32**(1): 36-40 (2010).
18. Hardwick R. N., et al. Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Non-Alcoholic Fatty Liver Disease. *Drug Metab Dispos* (2010).
19. Ibarra J. A., et al. Induction of Salmonella pathogenicity island 1 under different growth conditions can affect Salmonella-host cell interactions in vitro. *Microbiology* **156**(Pt 4):1120-33 (2010).
20. Jeong I., et al. Role of ataxia telangiectasia mutated in insulin signalling of muscle-derived cell lines and mouse soleus. *Acta Physiol (Oxf)* **198**(4):465-75 (2010).
21. Kaizerman J. A., et al. Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. *Bioorg Med Chem Lett* **20**(15):4607-10 (2010).

QuantiGene® 2.0 Bibliography

22. Lachaud A. A., *et al.* Werner's syndrome helicase participates in transcription of phenobarbital-inducible CYP2B genes in rat and mouse liver. *Biochem Pharmacol* **79**(3):463-70 (2010).
23. Love K. T., *et al.* Lipid-like materials for low-dose, in vivo gene silencing. *Proc Natl Acad Sci U S A* (2010).
24. Lucas B. S., *et al.* Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists. *Bioorg Med Chem Lett* **20**(12):3618-22 (2010).
25. Monovich L., *et al.* A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. *FEBS Lett* **584**(3):631-7 (2010).
26. Murray L. A., *et al.* Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. *PLoS One* **5**(3):e9683 (2010).
27. Musunuru K., *et al.* From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature* **466**(7307):714-9 (2010).
28. Radaelli A., *et al.* Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. *J Transl Med* **8**:40 (2010).
29. Robertson B., *et al.* Specificity and functionality of microRNA inhibitors. *Silence* **1**(1):10 (2010).
30. Salomon W., *et al.* Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. *Nucleic Acids Res* (2010).
31. Sasu B. J., *et al.* Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. *Blood* **115**(17):3616-24 (2010).
32. Semple S. C., *et al.* Rational design of cationic lipids for siRNA delivery. *Nat Biotechnol* (2010).
33. Srivastava S., Chen L. A two-parameter generalized Poisson model to improve the analysis of RNA-seq data. *Nucleic Acids Res* **38**(17):e170 (2010).
34. Stevens A., *et al.* Epigenetic changes in the hypothalamic proopiomelanocortin and glucocorticoid receptor genes in the ovine fetus after periconceptional undernutrition. *Endocrinology* **151**(8):3652-64 (2010).
35. Swift S., *et al.* Absence of functional EpoR expression in human tumor cell lines. *Blood* **115**(21):4254-63 (2010).
36. Talbot D. C., *et al.* Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. *Clin Cancer Res* **16**(24):6150-8 (2010).
37. Wang L., *et al.* In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. *Drug Metab Dispos* **38**(3):448-58 (2010).
38. Yim H. W., *et al.* Branched-chain Assay for ER, PR, and HER2 RNA Levels is a Useful Adjunct in the Evaluation of ER, PR, and HER2 in Breast Cancer. *J Breast Cancer* **13**(3):267-74 (2010).

QuantiGene® 2.0 Bibliography

39. Yue X., *et al.* Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini. *Nat Chem Biol* **6**(8):621-9 (2010).
40. Zhang L., *et al.* A new biosimetric method: branched DNA-based quantitative detection of B1 DNA in mouse plasma. *Br J Radiol* **83**(992):694-701 (2010).
41. Zhang Y. K., *et al.* Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. *Toxicol Appl Pharmacol* **245**(3):326-34 (2010).
42. Zumbansen M., *et al.* First siRNA library screening in hard-to-transfect HUVEC cells. *J RNAi Gene Silencing* **6**(1):354-60 (2010).

2009

1. Beetz N., *et al.* Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. *J Clin Invest* **119**(12):3597-612 (2009).
2. Berrodin T. J., *et al.* Novel progesterone receptor modulators with gene selective and context-dependent partial agonism. *Biochem Pharmacol* **77**(2):204-15 (2009).
3. Buckley D. B., Klaassen C. D. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. *Drug Metab Dispos* **37**(4):847-56 (2009).
4. Buckley D. B., Klaassen C. D. Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. *Drug Metab Dispos* **37**(4):834-40 (2009).
5. Champion S. N., *et al.* Effect of allyl alcohol on hepatic transporter expression: Zonal patterns of expression and role of Kupffer cell function. *Toxicology and Applied Pharmacology* **236**:49-58 (2009).
6. Chapuis J., *et al.* Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. *Mol Psychiatry* **14**(11):1004-16 (2009).
7. Cheng X., Klaassen C. D. Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. *Drug Metab Dispos* **37**(11):2178-85 (2009).
8. Cui Y. J., *et al.* Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. *Drug Metab Dispos* **37**(1):203-10 (2009).
9. Cui Y. J., *et al.* Ontogenic expression of hepatic Ahr mRNA is associated with histone H3K4 di-methylation during mouse liver development. *Toxicol Lett* **189**(3):184-90 (2009).
10. Ellison D. W., *et al.* Limited transcriptional responses of *Rickettsia rickettsii* exposed to environmental stimuli. *PLoS One* **4**(5):e5612 (2009).

QuantiGene® 2.0 Bibliography

11. Fortin M., *et al.* A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. *Respir Res* **10**: 39 (2009).
12. Grunt T. W., *et al.* Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. *Biochem Biophys Res Commun* **385**(3):454-9 (2009).
13. Haag J., *et al.* Efficient non-viral transfection of primary human adult chondrocytes in a high-throughput format. *Osteoarthritis Cartilage* **17**(6):813-7 (2009).
14. Kanashiro-Takeuchi R. M., *et al.* Sex-Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial Infarction. *Clin Transl Sci* **2**(2): 134-42 (2009).
15. Kwara A., *et al.* Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation. *J Clin Pharmacol* **49**(9):1079-90 (2009).
16. Lu B., *et al.* Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. *Urology* **74**(5):1156-61 (2009).
17. Mahmoudi S., *et al.* Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. *Mol Cell* **33**(4):462-71 (2009).
18. Mane S. P., *et al.* Transcriptome sequencing of the Microarray Quality Control (MAQC) RNA reference samples using next generation sequencing. *BMC Genomics* **10**(1):264 (2009).
19. Passioura T., *et al.* Interfering ribonucleic acids that suppress expression of multiple unrelated genes. *BMC Biotechnol* **9**(1):57 (2009).
20. Shinonaga H., *et al.* Pochonins K–P: new radicicol analogues from *Pochonia chlamydosporia* var. *chlamydosporia* and their WNT-5A expression inhibitory activities. *Tetrahedron* **65**:3446–53 (2009).
21. Shinonaga H., *et al.* Synthesis and structure-activity relationships of radicicol derivatives and WNT-5A expression inhibitory activity. *Bioorg Med Chem* **17**(13):4622-35 (2009).
22. Shinonaga H., *et al.* The search for a hair-growth stimulant: new radicicol analogues as WNT-5A expression inhibitors from *Pochonia chlamydosporia* var. *chlamydosporia*. *Tetrahedron Letters* **50**:108-10 (2009).
23. Surguladze D., *et al.* Tumor necrosis factor- α and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. *Cancer Res* **69**(14):5643-7 (2009).
24. Tanaka Y., *et al.* ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. *Toxicol Sci* **108**(2):247-57 (2009).
25. Vickers A. E., Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. *Toxicol Pathol* **37**(1):78-88 (2009).

QuantiGene[®] 2.0 Bibliography

26. Zhu J., *et al.* Regulation of apolipoprotein AI (apoAI) processing by Procollagen C-proteinase enhancer (PCPE2) and bone morphogenetic protein-1 (BMP-1). *J Lipid Res* (2009).

2008

1. Aagaard L. A., *et al.* Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. *Gene Ther* **15**(23):1536-49 (2008).
2. Akinc A., *et al.* A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat Biotechnol* **26**(5):561-9 (2008).
3. Aleksunes L. M., *et al.* Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. *Toxicol Appl Pharmacol* **226**(1):74-83 (2008).
4. Aleksunes L. M., *et al.* Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. *Toxicology* **250**(2-3):82-8 (2008).
5. Aleksunes L. M., Cui Y., Klaassen C. D. Prominent Expression of Xenobiotic Efflux Transporters in Mouse Extraembryonic Fetal Membranes Compared to Placenta. *Drug Metab Dispos* (2008).
6. Aleku M., *et al.* Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. *Cancer Res* **68**(23):9788-98 (2008).
7. Alnouti Y., Klaassen C. D. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. *J Pharmacol Exp Ther* **324**(2):612-21 (2008).
8. Alnouti Y., Klaassen C. D. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. *Toxicol Sci* **101**(1):51-64 (2008).
9. Anderson E., *et al.* Identifying siRNA-induced off-targets by microarray analysis. *Methods Mol Biol* **442**:45-63 (2008).
10. Anderson E. M., *et al.* Experimental validation of the importance of seed complement frequency to siRNA specificity. *Rna* **14**(5):853-61 (2008).
11. Arikawa E., *et al.* Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. *BMC Genomics* **9**:328 (2008).
12. Beilke L. D., *et al.* Minimal Role of Hepatic Transporters in the Hepatoprotection against LCA-Induced Intrahepatic Cholestasis. *Toxicol Sci* **102**(1):196-204 (2008).
13. Calcagno A. M., *et al.* Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. *Br J Cancer* **98**(9):1515-24 (2008).

QuantiGene[®] 2.0 Bibliography

14. Chae Y. K., *et al.* Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML). *PLoS ONE* **3**(7):e2594 (2008).
15. Cheng Q., *et al.* Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. *Mol Pharm* **5**(1):77-91 (2008).
16. Cheng X., Klaassen C. D. Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. *Toxicol Sci* **106**(1):29-36 (2008).
17. Cheng X. Klaassen C. D. Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. *Toxicol Sci* **106**(1):37-45 (2008).
18. Chung J. Y., *et al.* Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. *J Histochem Cytochem* **56**(11):1033-42 (2008).
19. Crombez L., *et al.* A New Potent Secondary Amphipathic Cell-penetrating Peptide for siRNA Delivery Into Mammalian Cells. *Mol Ther* (2008).
20. Eastham L. L., Mills C. N., Niles R. M. PPARalpha/gamma Expression and Activity in Mouse and Human Melanocytes and Melanoma Cells. *Pharm Res* (2008).
21. Fisher C. D., *et al.* Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. *Arch Toxicol* **82**(12):959-64 (2008).
22. Frank-Kamenetsky M., *et al.* Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proc Natl Acad Sci U S A* (2008).
23. Grueneberg D. A., *et al.* Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. *Proc Natl Acad Sci U S A* **105**(43):16490-5 (2008).
24. Gyamfi M. A., *et al.* Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. *Toxicol Appl Pharmacol* (2008).
25. Hart S. N., *et al.* Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. *Pharmacogenet Genomics* **18**(1):11-24 (2008).
26. Halpern M. D., Dvorak B. Does Abnormal Bile Acid Metabolism Contribute to NEC? *Semin Perinatol* **32**(2):114-21 (2008).
27. Honda M., *et al.* Specific knockdown of m-calpain blocks myogenesis with cDNA deduced from the corresponding RNAi. *Am J Physiol Cell Physiol* (2008).
28. Hubbard K., *et al.* Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis. *BMC Cancer* **8**:133 (2008).
29. Jonson A. L., *et al.* Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. *Gynecol Oncol* (2008).
30. Knight T. R., Choudhuri S., Klaassen C. D. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. *Toxicol Sci* **106**(2):329-38 (2008).

QuantiGene® 2.0 Bibliography

31. Knudsen B. S., *et al.* Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues. *J Mol Diagn* (2008).
32. Lee A. C., *et al.* Electrochemical Branched-DNA Assay for Polymerase Chain Reaction-Free Detection and Quantification of Oncogenes in Messenger RNA. *Anal Chem* (2008).
33. Lickteig A. J., *et al.* Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. *Life Sci* **83**(1-2):59-64 (2008).
34. Lorenzi P. L., *et al.* Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. *Mol Cancer Ther* **7**(10):3123-8 (2008).
35. Lu H., Klaassen C. Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats. *Drug Metab Dispos* **36**(1):16-23 (2008).
36. Lu H., *et al.* Characterization of Organic Anion Transporting Polypeptide 1b2-null Mice: Essential Role in Hepatic Uptake/Toxicity of Phalloidin and Microcystin-LR. *Toxicol Sci* (2008).
37. Maher J. M., *et al.* Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. *Toxicol Sci* **106**(2):319-28 (2008).
38. Merrell M. D., *et al.* The Nrf2 activator oltipraz also activates the constitutive androstane receptor. *Drug Metab Dispos* **36**(8):1716-21 (2008).
39. Migliaccio C. T., *et al.* The IL-4Ralpha pathway in macrophages and its potential role in silica-induced pulmonary fibrosis. *J Leukoc Biol* **83**(3):630-9 (2008).
40. Moore M., *et al.* Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. *J Pharm Biomed Anal* (2008).
41. Nair A., *et al.* A rapid and efficient branched DNA hybridization assay to titer lentiviral vectors. *J Virol Methods* **153**(2):269-72 (2008).
42. Querbes W., *et al.* Direct CNS Delivery of siRNA Mediates Robust Silencing in Oligodendrocytes. *Oligonucleotides* (2008).
43. Robbins M., *et al.* Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. *Hum Gene Ther* (2008).
44. Ryan M. C., *et al.* SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies. *BMC Bioinformatics* **9**:313 (2008).
45. Sano M., *et al.* Expression of Long Anti-HIV-1 Hairpin RNAs for the Generation of Multiple siRNAs: Advantages and Limitations. *Mol Ther* **16**(1):170-7 (2008).
46. Shou M., *et al.* Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. *Drug Metab Dispos* **36**(11):2355-70 (2008).

QuantiGene[®] 2.0 Bibliography

6. Cheng X., *et al.* Endocrine regulation of gender-divergent mouse organic anion-transporting polypeptide (Oatp) expression. *Mol Pharmacol* **70**(4):1291-7 (2006).
7. Conrad P. G., Chavli R. V., Givens R. S. Caged substrates applied to high content screening: an introduction with an eye to the future. *Methods Mol Biol* **356**:253-66 (2006).
8. Das P. C., *et al.* Fipronil induces CYP isoforms and cytotoxicity in human hepatocytes. *Chem Biol Interact* **164**(3):200-14 (2006).
9. Deng D. X., *et al.* Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli. *Circ Res* **98**(2):200-8 (2006).
10. Dotzlauf J., *et al.* Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase. *Hybridoma (Larchmt)* **25**(3):139-44 (2006).
11. Fedorov Y., *et al.* Off-target effects by siRNA can induce toxic phenotype. *RNA* **12**(7):1188-96 (2006).
12. Ferrari N., *et al.* Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. *Ann N Y Acad Sci* **1082**:91-102 (2006).
13. Fortin M., *et al.* Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. *Oligonucleotides* **16**(3):203-12 (2006).
14. Groves C. E., *et al.* Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. *J Pharmacol Exp Ther* **316**(2):743-52 (2006).
15. Hinfray N., *et al.* Brain and gonadal aromatase as potential targets of endocrine disrupting chemicals in a model species, the zebrafish (*Danio rerio*). *Environ Toxicol* **21**(4):332-7 (2006).
16. Judge A. D., *et al.* Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. *Mol Ther* **13**(3):494-505 (2006).
17. Kolachala V. L., *et al.* Adenosine 2b receptor (A2bR) signals through adenylate cyclase (AC) 6 isoform in the intestinal epithelial cells. *Biochim Biophys Acta* **1760**(7):1102-8 (2006).
18. Laville N., *et al.* Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. *Toxicology* **228**(1):98-108 (2006).
19. Lin X., *et al.* 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. *Oncogene* (2006).
20. Lorenzi P. L., *et al.* Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. *Mol Cancer Ther* **5**(11):2613-23 (2006).

QuantiGene® 2.0 Bibliography

36. Stanley L. A., *et al.* PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. *Drug Metab Rev* **38**(3):515-97 (2006).
37. Tanaka Y., *et al.* Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. *Transplantation* **82**(2):258-66 (2006).
38. Tsuji P. A., Walle T. Inhibition of benzo[a]pyrene-activating enzymes and DNA binding in human bronchial epithelial BEAS-2B cells by methoxylated flavonoids. *Carcinogenesis* **27**(8):1579-85 (2006).
39. Yang W., *et al.* Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. *Biotechniques* **40**(4):481-6 (2006).
40. Yu M., Yeh J., Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. *Cancer Res* **66**(13):6722-31 (2006).
41. Yu Y., *et al.* A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. *J Immunol Methods* **316**(1-2):8-17 (2006).
42. Yudit M. R., *et al.* Selective and opposing actions of progesterone receptor isoforms in human endometrial stromal cells. *Mol Cell Endocrinol* **247**(1-2):116-26 (2006).
43. Zheng Z., Luo Y., McMaster G. K. Sensitive and quantitative measurement of gene expression directly from a small amount of whole blood. *Clin Chem* **52**(7):1294-302 (2006).
44. Zimmermann T. S., *et al.* RNAi-mediated gene silencing in non-human primates. *Nature* **441**(7089):111-4 (2006).

2005

1. Aleksunes L. M., *et al.* Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. *Toxicol Sci* **83**(1):44-52 (2005).
2. Alikhani M., Alikhani Z., Graves D. T. FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. *J Biol Chem* **280**(13):12096-102 (2005).
3. Augustine L. M., *et al.* Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. *Drug Metab Dispos* **33**(1):182-9 (2005).
4. Burris T. P., *et al.* The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. *Mol Pharmacol* **67**(3):948-54 (2005).
5. Cheng X., *et al.* Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). *Drug Metab Dispos* **33**(7):1062-73 (2005).
6. Cheng X., *et al.* Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate

QuantiGene[®] 2.0 Bibliography

20. Thukral S. K., *et al.* Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. *Toxicol Pathol* **33**(3): 343-55 (2005).
21. Vermeulen A., *et al.* The contributions of dsRNA structure to Dicer specificity and efficiency. *Rna* **11**(5): 674-82 (2005).
22. Wen X., Walle T. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. *Carcinogenesis* **26**(10): 1774-81 (2005).
23. Wen X., Walle U. K., Walle T. 5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells. *Carcinogenesis* **26**(4): 803-9 (2005).

2004

1. Buist S. C., Klaassen C. D. Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. *Drug Metab Dispos* **32**(6): 620-5 (2004).
2. Cherrington N. J., *et al.* Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. *Drug Metab Dispos* **32**(7): 734-41 (2004).
3. Dieter M. Z., *et al.* Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. *Comp Biochem Physiol C Toxicol Pharmacol* **139**(4): 209-18 (2004).
4. Gruber J. Functional gene analysis in cultured vertebrate cells using siRNA mediated gene silencing. (2004).
5. Heijne W. H., *et al.* Bromobenzene-induced hepatotoxicity at the transcriptome level. *Toxicol Sci* **79**(2): 411-22 (2004).
6. Li N., *et al.* Down-regulation of mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) mRNA by lipopolysaccharide through the toll-like receptor 4 (TLR4). *Drug Metab Dispos* **32**(11): 1265-71 (2004).
7. Li N., Klaassen C. D. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide. *Mol Pharmacol* **66**(3): 694-701 (2004).
8. Lu H., Chen C., Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. *Drug Metab Dispos* **32**(12): 1455-61 (2004).
9. Reynolds A., *et al.* Rational siRNA design for RNA interference. *Nat Biotechnol* **22**(3): 326-30 (2004).
10. Sakamoto S., *et al.* Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. *Endocrinology* **145**(6): 2929-40 (2004).
11. Soutschek J., *et al.* Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**(7014): 173-8 (2004).
12. Wright S. H., *et al.* Functional map of TEA transport activity in isolated rabbit renal proximal tubules. *Am J Physiol Renal Physiol* **287**(3): F442-51 (2004).

QuantiGene® 2.0 Bibliography

2003

1. Bramlett K. S., *et al.* A natural product ligand of the oxysterol receptor, liver X receptor. *J Pharmacol Exp Ther* **307**(1):291-6 (2003).
2. Buist S. C., Cherrington N. J., Klaassen C. D. Endocrine regulation of rat organic anion transporters. *Drug Metab Dispos* **31**(5):559-64 (2003).
3. Cao G., *et al.* Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. *J Biol Chem* **278**(2):1131-6 (2003).
4. Chen C., Hennig G. E., Manautou J. E. Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats. *Drug Metab Dispos* **31**(6):798-804 (2003).
5. Chen C., Staudinger J. L., Klaassen C. D. Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16 alpha-carbonitrile. *Drug Metab Dispos* **31**(7):908-15 (2003).
6. Cherrington N. J., *et al.* Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. *Drug Metab Dispos* **31**(11):1315-9 (2003).
7. Choudhuri S., *et al.* Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. *Drug Metab Dispos* **31**(11):1337-45 (2003).
8. Khvorova A., Reynolds A., Jayasena S. D. Functional siRNAs and miRNAs exhibit strand bias. *Cell* **115**(2):209-16 (2003).
9. Leazer T. M., Klaassen C. D. The presence of xenobiotic transporters in rat placenta. *Drug Metab Dispos* **31**(2):153-67 (2003).
10. Sakamoto S., *et al.* Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. *J Biomol Screen* **8**(6):701-11 (2003).
11. Shelby M. K., *et al.* Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. *Drug Metab Dispos* **31**(3):326-33 (2003).
12. Slitt A. L., *et al.* Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. *Drug Metab Dispos* **31**(9):1176-86 (2003).
13. Tsai S. P., *et al.* Nucleic acid capture assay, a new method for direct quantitation of nucleic acids. *Nucleic Acids Res* **31**(6):e25 (2003).
14. Wu S. J., *et al.* Quantitation of CYP1A1 and 1B1 mRNA in polycyclic aromatic hydrocarbon-treated human T-47D and HepG2 cells by a modified bDNA assay using fluorescence detection. *Anal Biochem* **312**(2):162-6 (2003).

QuantiGene® 2.0 Bibliography

15. Luo G., *et al.* CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. *Drug Metab Dispos* **30**(7):795-804 (2002).
16. Park J. D., Cherrington N. J., Klaassen C. D. Intestinal absorption of cadmium is associated with divalent metal transporter 1 in rats. *Toxicol Sci* **68**(2):288-94 (2002).
17. Park J. D., Habeebu S. S., Klaassen C. D. Testicular toxicity of di-(2-ethylhexyl)phthalate in young Sprague-Dawley rats. *Toxicology* **171**(2-3):105-15 (2002).
18. Slitt A. L., *et al.* Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. *Drug Metab Dispos* **30**(2):212-9 (2002).
19. Vansell N. R., Klaassen C. D. Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation. *Drug Metab Dispos* **30**(3):240-6 (2002).
20. Wagaman P. C., Leong M. A., Simmen K. A. Development of a novel influenza A antiviral assay. *J Virol Methods* **105**(1):105-14 (2002).
21. Xiang H., *et al.* Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. *Oncogene* **21**(22):3611-9 (2002).
22. Zhang Y., *et al.* Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology. *Mol Genet Metab* **77**(1-2):150-8 (2002).

2001

1. Allan G. F., *et al.* Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. *Steroids* **66**(9):663-71 (2001).
2. Player A. N., *et al.* Single-copy gene detection using branched DNA (bDNA) in situ hybridization. *J Histochem Cytochem* **49**(5):603-12 (2001).
3. Rausch-Derra L. C., *et al.* Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2. *Hepatology* **33**(6):1469-78 (2001).
4. Sen A., *et al.* Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. *J Cell Biochem* **81**(2):312-9 (2001).
5. Takiguchi M., *et al.* Cyproterone acetate induces a cellular tolerance to cadmium in rat liver epithelial cells involving reduced cadmium accumulation. *Toxicology* **165**(1):13-25 (2001).

QuantiGene® 2.0 Bibliography

2000

1. Bramlett K. S., Yao S., Burris T. P. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. *Mol Genet Metab* **71**(4):609-15 (2000).
2. Hartley D. P., Klaassen C. D. Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. *Drug Metab Dispos* **28**(5):608-16 (2000).
3. Warrior U., *et al.* Application of QuantiGene nucleic acid quantification technology for high throughput screening. *J Biomol Screen* **5**(5):343-52 (2000).
4. Wentworth J. M., Burris T. P., Chatterjee V. K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. *J Endocrinol* **164**(2):R7-10 (2000).
5. Zhou L., *et al.* A branched DNA signal amplification assay to quantitate messenger RNA of human uncoupling proteins 1, 2, and 3. *Anal Biochem* **282**(1):46-53 (2000).

1999

1. Burris T. P., *et al.* A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. *Mol Endocrinol* **13**(3):410-7 (1999).
2. Todd M. D., *et al.* Toxicity Screening of a Combinatorial Library: Correlation of Cytotoxicity and Gene Induction to Compound Structure. *J Biomol Screen* **4**(5):259-68 (1999).